title: Comparison of treatment with preservative-free versus preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops after cataract surgery in patients with preexisting dry-eye syndrome.
abstract: OBJECTIVE
  To compare treatment with preservative-free and preserved sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops after cataract surgery in patients with preexisting dry-eye syndrome.
  
  
  METHODS
  Bucheon St. Mary's Hospital, Catholic University of Korea, Seoul, Korea.
  
  
  METHODS
  Randomized controlled study.
  
  
  METHODS
  Patients with cataract and dry-eye syndrome were randomly divided into 2 groups. Group 1 patients were treated with preservative-free sodium hyaluronate 0.1% and preservative-free fluorometholone 0.1% eyedrops 4 times a day in the first month and twice a day in the second month. Group 2 patients were treated with preserved eyedrops using the same schedule. Ocular Surface Disease Index (OSDI) score, tear-film breakup time (TBUT), Schirmer I test, corneal fluorescein staining, impression cytology, and antioxidant and inflammatory cytokine activities in tears were evaluated.
  
  
  RESULTS
  Both groups comprised 40 patients. At 2 months, the OSDI score, TBUT, Schirmer I score, fluorescein staining score, impression cytology findings, and goblet cell count were significantly better in Group 1 than in Group 2 (P<.05). The interleukin-1β and tumor necrosis factor-α concentrations were significantly less in the tears of Group 1 patients than in the tears of Group 2 patients, and catalase and superoxide dismutase 2 fluorescence intensities were significantly greater in the tears of Group 1 patients than in the tears of Group 2 patients (P<.05).
  
  
  CONCLUSIONS
  Preservative-free sodium hyaluronate 0.1% and fluorometholone 0.1% eyedrops can improve the symptoms and signs of dry-eye syndrome after cataract surgery. Preservative-free fluorometholone eyedrops may have antiinflammatory and antioxidant effects in tears of patients with dry-eye syndrome.
  
  
  BACKGROUND
  No author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: From the Department of Ophthalmology & Visual Science (Jee, Park, M.S. Kim, E.C. Kim) and the Institute of Clinical Medicine Research (Lee), College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Donghyun
authors.initials: D
authors.lastname: Jee
authors.affiliation: From the Department of Ophthalmology & Visual Science (Jee, Park, M.S. Kim, E.C. Kim) and the Institute of Clinical Medicine Research (Lee), College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Minji
authors.initials: M
authors.lastname: Park
authors.affiliation: From the Department of Ophthalmology & Visual Science (Jee, Park, M.S. Kim, E.C. Kim) and the Institute of Clinical Medicine Research (Lee), College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Hee Jin
authors.initials: HJ
authors.lastname: Lee
authors.affiliation: From the Department of Ophthalmology & Visual Science (Jee, Park, M.S. Kim, E.C. Kim) and the Institute of Clinical Medicine Research (Lee), College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Man Soo
authors.initials: MS
authors.lastname: Kim
authors.affiliation: From the Department of Ophthalmology & Visual Science (Jee, Park, M.S. Kim, E.C. Kim) and the Institute of Clinical Medicine Research (Lee), College of Medicine, The Catholic University of Korea, Seoul, Korea. Electronic address: eunchol@hanmail.net.
authors.forename: Eun Chul
authors.initials: EC
authors.lastname: Kim
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016022:Case-Control Studies; D002374:Catalase / Q000378:metabolism; D004338:Drug Combinations; D015352:Dry Eye Syndromes / Q000150:complications / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D005469:Fluorometholone / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D006820:Hyaluronic Acid / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000378:metabolism; D019654:Lens Implantation, Intraocular; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D018918:Phacoemulsification; D011182:Postoperative Care; D011310:Preservatives, Pharmaceutical / Q000627:therapeutic use*; D013482:Superoxide Dismutase / Q000378:metabolism; D013666:Tears / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D055675:Viscosupplements / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D005938:Glucocorticoids; D053583:Interleukin-1beta; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D014409:Tumor Necrosis Factor-alpha; D055675:Viscosupplements; D006820:Hyaluronic Acid; D002374:Catalase; D013482:Superoxide Dismutase; D005469:Fluorometholone